Restrictin-P: the first member of a putative family of novel inhibitors.

Abstract

MBA-2.1 cells produce an activity, designated restrictin-P, which is specifically inhibitory to the growth of plasmacytomas and mature B cell lymphomas. We examined whether the activity of this stromally derived glycoprotein could be attributed to a well-characterized growth factor. Restrictin-P-producing cells were therefore screened for the expression of transcripts of a variety of growth suppressors. With the exception of TGF-beta 1, none was produced in detectable amounts by these cells. Furthermore, recombinant forms of the inhibitory molecules tested did not exert a biological effect similar to that of restrictin-P. Restrictin-P was shown to elicit a G0/G1 arrest in the cell cycle of its target cells, as soon as 24 h after their exposure to the inhibitor. This effect could not be mimicked by TGF-beta 1. We suggest that restrictin-P is part of a novel family of inhibitors which are required for the maintenance of cell-type specificities in the hematopoietic microenvironment.

• Authors: J Honigwachs-Sha'anani, N Brosh, R Kompier, A Kadouri, D Zipori
• Journal: Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 628 Pg. 287-97 ( 1991) ISSN: 0077-8923 [Print] United States
• PMID: 2069309 (Publication Type: Journal Article)

Chemical References

• Cytokines
• Glycoproteins
• Growth Inhibitors
• Intercellular Signaling Peptides and Proteins
• RNA, Messenger
• Transforming Growth Factor beta
• restrictin-P

Topics

• Animals
• Cell Cycle (drug effects)
• Cell Line
• Cytokines (genetics)
• Flow Cytometry
• Glycoproteins (genetics, isolation & purification, pharmacology)
• Growth Inhibitors (genetics, isolation & purification, pharmacology)
• Intercellular Signaling Peptides and Proteins
• Plasmacytoma
• RNA, Messenger (genetics)
• Transforming Growth Factor beta (pharmacology)